logo
Powell's Successor May Struggle to Deliver the Rate Cuts Trump Wants

Powell's Successor May Struggle to Deliver the Rate Cuts Trump Wants

Yahoo6 days ago
(Bloomberg) -- Close Federal Reserve watchers have a message for anyone who thinks the next leader of the US central bank will deliver lower borrowing costs on a silver platter: Don't count on it.
Are Tourists Ruining Europe? How Locals Are Pushing Back
Can Americans Just Stop Building New Highways?
Singer Akon's Failed Futuristic City in Senegal Ends Up a $1 Billion Resort
Denver City Hall Takes a Page From NASA
Philadelphia Trash Piles Up as Garbage Workers' Strike Drags On
While it's an unlikely outcome, some investors have staked out positions in futures markets that will profit if interest rates drop immediately after Jerome Powell's term as chair ends in May 2026. The trade has been fueled by President Donald Trump's pledge to nominate 'somebody that wants to cut rates.'
Those investors have targeted futures contracts linked to the Secured Overnight Financing Rate, or SOFR, which closely tracks the benchmark federal funds rate. They've sold off contracts that expire prior to Powell's exit and piled into contracts that expire just after the expected arrival of a Trump-appointed chair.
It's a trade that takes a chance on Trump getting his way, shrugging off how the central bank goes about setting rates.
A chair 'can't act like a dictator,' said Mark Gertler, an economics professor at New York University who has co-authored papers with former Fed Chair Ben Bernanke and former Vice Chair Richard Clarida. 'He can't call in the Marines or anything like that.'
Adjusting rates, Gertler pointed out, requires the support of a majority on the Federal Open Market Committee. Nineteen policymakers participate in FOMC meetings and 12 vote. In other words, the new chair will have to win over their colleagues with a reasonable case for cutting.
So far this year, Fed officials have agreed to hold borrowing costs steady in a range of 4.25% to 4.5%. But, as rate projections reveal, policymakers appear split over the outlook for cuts over the rest of the year, largely over differing views on how Trump's tariffs might affect inflation.
Ten policymakers — those more inclined to see the impact of tariffs on prices as temporary — expect two or three cuts by year's end. Two others see just one cut as appropriate and seven expect the benchmark rate to stay where it is. For next year, the range widens, with the upper boundary of the federal funds rate projected to finish 2026 anywhere from 2.75% to 4.25%.
The projections, being anonymous, can't be linked with certainty to individual policymakers.
'It's obviously a concern that the Fed will be less independent, certainly,' said Michael Feroli, chief US economist at JPMorgan Chase & Co. 'Whether one person, even if that's the chair, can immediately get the committee to agree to a big change in policy, I think that might be more difficult.'
Lining Up Votes
Trump's pick to replace Powell won't be the only person inclined to support his call for cuts. Fed Governor Michelle Bowman — whom Trump placed on the board in 2018 and promoted to the central bank's top regulatory job last month — has so far this year supported holding rates steady, but recently said it might be appropriate to cut later this month. So, too, has Governor Christopher Waller, another Trump appointee.
The president may use the vacancy created in January when Fed Governor Adriana Kugler's term expires to place his pick for chair on the Board of Governors. He'll then get one more opening to fill if Powell resigns from his underlying post as a governor. That's what outgoing chairs typically do, but Powell has declined to say whether he'll exit altogether.
But even if Powell departs, that doesn't add up to enough votes to make additional cuts. Whether others go along with lowering rates will depend more on what actually happens in the economy. And it could be difficult to peel away other policymakers one-by-one.
Dissents aren't especially rare, but in an institution that values broad-based agreement, especially when policy shifts, votes are rarely deeply split.
'At the end of the day it's a committee decision, and whoever the next chair is, he is going to have to build a consensus,' said Brett Ryan, US senior economist at Deutsche Bank Securities.
Will Trade War Make South India the Next Manufacturing Hub?
'Our Goal Is to Get Their Money': Inside a Firm Charged With Scamming Writers for Millions
'Telecom Is the New Tequila': Behind the Celebrity Wireless Boom
Pistachios Are Everywhere Right Now, Not Just in Dubai Chocolate
SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too
©2025 Bloomberg L.P.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Defi Tokens Are Soaring, Leaving Behind OG Coins Like LTC, BCH and XMR
Defi Tokens Are Soaring, Leaving Behind OG Coins Like LTC, BCH and XMR

Yahoo

time7 minutes ago

  • Yahoo

Defi Tokens Are Soaring, Leaving Behind OG Coins Like LTC, BCH and XMR

Bitcoin's surge to an all time high on Thursday evoked mixed reactions from altcoins, with some outperforming the largest cryptocurrency by market cap and others lagging behind. And that's split along industry lines. Tokens associated with decentralized finance (DeFi) and those from layer-2 blockchains are outperforming as investors transition to a risk-on approach. Others, such as tron (TRX), bitcoin cash (BCH), litecoin (LTC) and monero (XMR) are, in comparison, barely moving. Even solana (SOL), the darling of the previous drive to record highs, seems to be taking a back seat, rising just 3.9% while the likes of sei (SEI), ethena (ENA) and optimism (OP) are celebrating gains of as much as 28%. "Altcoins are leading the pack in this latest rally," Thomas Perfumo, Kraken's global economist, said in an email. A drop in bitcoin dominance is "reinforcing a broad-based rally with altcoins leading the charge." During the 2017 and 2021 runs to record highs, bitcoin dominance — a measure of BTC's share of the total crypto market —rose rapidly. On Thursday's rally, it fell to 63.5% from 64%, indicating a shift in emphasis toward the altcoin market Crypto markets are cyclical by nature. They run without interruption 24 hours a day against a backdrop of high volatility and low liquidity which can create an emotional trading environment. In previous cycles, altcoins often moved in unison, rising as bitcoin consolidated and dropping en masse when it rose or fell. This time, however, seems different, possibly due to the increased participation of institutions in the the industry. The rise in DeFi tokens can be attributed to increasing institutional interest in ether (ETH), which could pave the way for a search for yield with firms battling to secure the highest returns. The same can be said for layer-2 networks. As institutions run into the Ethereum blockchain's issues with latency and efficiency, they may consider networks like Arbitrum that allow liquidity to flow from decentralized exchanges to staking protocols at a fast rate. That network's ARB token is up 15% in the past 24 hours. Still, Petr Kozyakov, CEO at payments firm Mercuryo, said the rise in altcoins will be short-lived. "While altcoins are also in the green with Ethereum spiking past the $3,000 mark, the underlying 'orange pill' narrative remains steadfastly in place," he said. "Bitcoin's growing status as a store of value is one that more and more big players and institutions are simply unable to ignore." That's not a narrative that finds much support from Arthur Hayes, the BitMEX founder turned fund manager. 'Get ready for a monster alt season,' he told his followers on X after predicting that ETH would reach $10,000 this cycle. If Hayes' prediction holds true, bitcoin could face short-term difficulty as liquidity will inevitably flow into the altcoin market as traders attempt to capture speculative gains. This could also be a hammer blow to the old-school crypto coins, which all lack major catalysts for a boost. Sign in to access your portfolio

Revolutionizing Anesthesia Drug Management and Integrity
Revolutionizing Anesthesia Drug Management and Integrity

Medscape

time16 minutes ago

  • Medscape

Revolutionizing Anesthesia Drug Management and Integrity

Stocking and restocking anesthesia carts is tedious and meticulous — and it's highly regulated. Anesthesiologists have direct and extensive access to controlled drugs in a hospital setting, particularly potent opioids and sedatives, which makes these processes vulnerable to the potential of abuse. Within the anesthesia ecosystem, the doctor has a partner in the stocking and restocking process, and that's the hospital pharmacy staff. This team has so much reporting to do: logging which medications were used by which operating teams and on which patients — data that ultimately get reported to the Drug Enforcement Administration. Errors in any part of the dispensing, stocking, and securing process could result in waste, fines, medication errors, or worse. Hospitals have been on the search for help. Several companies have focused on what's called RAIN RFID. The technology uses passive ultrahigh frequency waves to essentially perform the function of Bluetooth or Wi-Fi for short-range device communication. It's available to hospitals to help with everything from patient tracking to equipment security and compliance. For anesthesia departments, the company Intelliguard created what it calls the Mira Ecosystem. It's built on RAIN RFID and monitors each vial of medication through its entire journey, filling clinical, compliance, and supply chain functions. Tray Setups and Refills Are Quick, Easy, and Traceable According to Intelliguard, about 90% of its systems are currently deployed to serve anesthesia departments. When vials of medication arrive at the pharmacy, a technician applies the Mira tag to each vial, and immediately, the system begins tracking each individual one. 'Our system reads each of the 96-bit unique IDs and then associates those unique IDs with the medication. So now each of those IDs is associated with rocuronium, for example, and the company that made it, the serial number, and the expiration and the lot number,' said Paul Elizondo, Intelliguard's chief innovation officer. 'From then on, when our system sees that 96-bit unique ID, it associates it with the medication in a database. It displays that on the screen, and we know exactly what that medication is now.' Paul Elizondo The system tracks each vial of medication throughout its journey at the hospital, giving pharmacy managers and hospital administrators instant, real-time visibility into where each vial is and when. In terms of daily pharmacy tasks, making up medication trays for anesthesiologists is made nearly foolproof, reducing medication errors. 'The hospitals using our system will place these RFID-tagged medications into the tray, then they will place that tray into our enclosure,' said Elizondo. 'In 6 seconds, we read every single tag in that tray, and we let them know if that formula, if what's in the tray, matches the formulary to which they're building right at that time.' The system can also check to ensure there are no expired or recalled medications in the tray. The real-time savings come, though, when the anesthesiologist returns the tray at the end of the day. Rady Children's Hospital in San Diego is using this system. Performance improvement pharmacist Ann McKinstry explained some of the ways that she's seen return on investment gains. 'Pinpointing the medication location has allowed for a more rapid response to expiry, recalls, and patient care events,' McKinstry said. 'Inpatient pharmacy inventory is tightened by offering a streamlined data review to analyze usage and reducing waste by tightening supply on hand. In addition, RFID tags allow accurate controlled substance reconciliation by monitoring usage, waste, and replenishment down to the minute.' Real-Time Tracking of Medication Location Saves a Life Knowing exactly where your medications are on a real-time basis isn't just important: It can be a matter of life and limb. For example, if a patient with a deadly North American pit viper bite is rolled into your emergency department, as happened at a Bartow, Florida hospital at 1 AM on May 4 — you'd definitely want to know if you have antivenom on hand. Bartow was out. They reached out to Prodigy Health, distributor of specialty pharmaceuticals that supplies medicines to hospitals on a consignment basis. Prodigy runs a 24-hour switchboard and uses RAIN to gain visibility into what is being dispensed by each hospital. The antivenom was quickly located at a hospital in Lutz, Florida, one that had a RAIN RFID cabinet. The request was made, the antivenom was transferred, and the day was saved. Ty Dishman Before this technology, 'This process was manual and time-consuming. Now, with reliable data integrating into our system every 6 seconds, we're able to provide immediate, confident answers to customer inquiries about medication availability and delivery timelines,' said Ty Dishman, CEO of Prodigy Health. 'Instead of saying, 'I think it's there — let me check and call you back,' we can act quickly and efficiently, ensuring life-saving medications are mobilized without delay.' The Competitive Landscape RFID systems are nothing new in the healthcare environment. They're commonly used to track medical equipment and inventory, as well as in staff badging systems. Its use in medication management is fairly recent. Terso Solutions offers a similar suite to the Mira Ecosystem, with the exception of Intelliguard's direct-to-operating room tray system; Avery Dennison Medical and Healthcare provides a wide range of pharmaceutical labeling options, and some options include RFID.

What You Need To Know Ahead of Tyson Foods' Earnings Release
What You Need To Know Ahead of Tyson Foods' Earnings Release

Yahoo

time21 minutes ago

  • Yahoo

What You Need To Know Ahead of Tyson Foods' Earnings Release

Valued at $19.3 billion by market cap, Springdale, Arkansas-based Tyson Foods, Inc. (TSN) operates as the biggest U.S. chicken company and produces, distributes, and markets chicken, beef, pork, as well as prepared foods. The farm products giant is expected to announce its third-quarter results before the markets open on Monday, Aug. 4. Ahead of the event, analysts expect Tyson Foods to deliver a profit of $0.79 per share, down 9.2% from $0.87 per share reported in the year-ago quarter. On the positive note, the company has a solid earnings surprise history and has surpassed the Street's bottom-line estimates in each of the past four quarters. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full fiscal 2025, analysts expect TSN to report an EPS of $3.83, up a staggering 23.6% from $3.10 reported in fiscal 2024. In fiscal 2026, its earnings are expected to further grow 10.7% year-over-year to $4.24 per share. TSN stock prices have dropped 5.2% over the past 52 weeks, notably underperforming the S&P 500 Index's ($SPX) 11.6% gains and the Consumer Staples Select Sector SPDR Fund's (XLP) 4.4% uptick during the same time frame. Tyson Foods' stock prices plunged 7.8% following the release of its mixed Q2 results on May 5. Although the company reported hikes in product prices, its volumes remained under pressure. This led to its overall topline remaining flat year-over-year at $13.1 billion, missing the consensus estimates by 61 basis points. Meanwhile, its gross profits took a hit due to rising cost of sales, and its operating cash flows for the quarter dropped 28.1% year-over-year to $846 million. However, its adjusted EPS of $0.92 surpassed the consensus estimates by 8.2%. The stock maintains a consensus 'Moderate Buy' rating overall. Of the 10 analysts covering the TSN stock, opinions include three 'Strong Buys' and seven 'Holds.' Its mean price target of $64 indicates a 17.8% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store